Supplemental material
Journal of Medical Economics
Volume 27, 2024 - Issue 1
Oncology
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States
, , 
, , , , & show all
Hélène Pariséc Medicus Economics LLC, Boston, MA, USACorrespondence[email protected]
https://orcid.org/0009-0006-4976-904X
https://orcid.org/0009-0006-4976-904X, Eric Zukc Medicus Economics LLC, Boston, MA, USAhttps://orcid.org/0009-0004-7403-3611
https://orcid.org/0009-0004-7403-3611, Danilo Di Maiob F. Hoffmann-La Roche, Basel, Switzerlandhttps://orcid.org/0009-0007-3975-508X
https://orcid.org/0009-0007-3975-508X, Sheila Shapourid Genentech, Inc., South San Francisco, CA, USAhttps://orcid.org/0009-0007-6964-4735
https://orcid.org/0009-0007-6964-4735, & Shih-Wen Lind Genentech, Inc., South San Francisco, CA, USAhttps://orcid.org/0000-0002-3727-430X
https://orcid.org/0000-0002-3727-430X show all